VAXCYTE INC (PCVX)
Health Care · Vaccine development and manufacturing · NASDAQ
Vaxcyte engineers next-generation bacterial vaccines using cell-free protein synthesis to create broader-spectrum, more immunogenic alternatives to existing vaccines.
What VAXCYTE INC does
Vaxcyte is a clinical-stage vaccine innovation company developing high-fidelity vaccines against bacterial diseases using its proprietary XpressCF cell-free protein synthesis platform. Unlike conventional cell-based manufacturing, the platform enables production of complex antigens with enhanced immunological properties. The company's primary pipeline focuses on broad-spectrum pneumococcal conjugate vaccines (PCVs) targeting the $8 billion global pneumococcal vaccine market.
Themes: ["Pneumococcal vaccines / bacterial infection prevention","Cell-free protein synthesis manufacturing","Broad-spectrum vaccine candidates"]
Fundamentals
- Price$59.83 as of 2026-07-09 close
- Market cap$8.7B as of 2026-07-10
- 1-year return+67.2% as of 2026-07-09 close
- ROE-32.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.21 as of 2026-07-10
Key risks (from latest filing)
["All vaccine candidates are in clinical or preclinical stages with uncertain regulatory approval pathways; VAX-31 is only in Phase 2 development","Dependence on novel XpressCF manufacturing platform that has not yet produced an approved vaccine, creating technological and commercial execution risk","Competition from established pneumococcal vaccine manufacturers (Pfizer, Merck, GSK) with approved products and market share in the $8 billion PCV market"]
Competitors & peers
- Pfizer (PFE) - Prevnar pneumococcal franchise
- Merck
- GlaxoSmithKline (GSK)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.